Long-term cellular memory immunity against Bordetella pertussis and other components of the DTP-IPV-Hib vaccine in Dutch children: comparison of a whole cell vaccine (WCV) with an acellular vaccine (ACV)

Conditions

Whooping cough/ Bordetella pertussis infection Infections and Infestations Whooping cough

van der Lee S, Sanders EAM, Berbers GAM, Buisman AM.

2017-12-0130 citations

10.1016/j.vaccine.2017.11.066

Differential T- and B-Cell Responses to Pertussis in Acellular Vaccine-Primed versus Whole-Cell Vaccine-Primed Children 2 Years after Preschool Acellular Booster Vaccination

Rose‐Minke Schure, Lotte H. Hendrikx, Lia G. H. de Rond, Kemal Öztürk, Elisabeth A. M. Sanders et al. (7 authors)

Clinical and Vaccine Immunology2013-07-0460 citations

10.1128/cvi.00270-13

T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children.

Schure RM, Hendrikx LH, de Rond LG, Oztürk K, Sanders EA, Berbers GA, Buisman AM.

2012-09-2648 citations

10.1128/cvi.00277-12

Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age.

Schure RM, de Rond L, Oztürk K, Hendrikx L, Sanders E, Berbers G, Buisman AM.

2012-07-3124 citations

10.1371/journal.pone.0041928

Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.

Hendrikx LH, Oztürk K, de Rond LG, Veenhoven RH, Sanders EA, Berbers GA, Buisman AM.

2010-12-2543 citations

10.1016/j.vaccine.2010.12.033

Interventions

This is an observational, cohort study. Recruitment will be carried out in two stages. Populations of children at different ages who already had received four vaccinations at 2, 3, 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both male and female children, aged 3 to 9 years old 2. Infants in good general health (eligible) who have been vaccinated according to the Dutch national vaccination programme 3. Provision of written informed consent by both parents and legal representatives

Exclusion criteria

Exclusion criteria: 1. Present evidence of serious disease(s) demanding immunosuppressive medical treatment, such as corticosteroids, that might interfere with the results of the study within 3 months 2. Any known primary or secondary immunodeficiency 3. Vaccination with any other vaccine than those used in the National Immunisation Programme (Rijks Vaccinatie Programma [RVP]) within a month before the blood sampling

Design outcomes

Primary

Measure	Time frame
B cell and T cell immune responses: Peripheral blood mononuclear cells (PBMC's) will be isolated from the blood samples. PBMC's will be divided in purified B cell populations and T cell populations. B cells will be cultured and memory B cells will be polyclonal stimulated. After 5 days stimulation, B cell memory responses will be measured against the various proteins of B pertussis (filamentous hemagglutinin adhesin [FHA], pertactin [PRN], pertussis toxin [PT], fimbriae [Fim], lipopolysaccharide [LPS]) by ELIspot assays and enzyme-linked immunosorbent assay (ELISA)/Luminex® of the culture supernatants. T cells will be stimulated with the various proteins of B. pertussis and at 24 hours and 5 days of culture, cells and supernatants will be harvested. Memory T cell responses will be measured by IFN-y and/or IL2 ELIspot assays. TH1/TH2 ratios will be measured by analysing cytokines in the culture supernatants by Luminex® bead protein assay or ELISA. All data collection will be completed by the end of 2010.	—

Measure

Time frame

B cell and T cell immune responses: Peripheral blood mononuclear cells (PBMC's) will be isolated from the blood samples. PBMC's will be divided in purified B cell populations and T cell populations. B cells will be cultured and memory B cells will be polyclonal stimulated. After 5 days stimulation, B cell memory responses will be measured against the various proteins of B pertussis (filamentous hemagglutinin adhesin [FHA], pertactin [PRN], pertussis toxin [PT], fimbriae [Fim], lipopolysaccharide [LPS]) by ELIspot assays and enzyme-linked immunosorbent assay (ELISA)/Luminex® of the culture supernatants. T cells will be stimulated with the various proteins of B. pertussis and at 24 hours and 5 days of culture, cells and supernatants will be harvested. Memory T cell responses will be measured by IFN-y and/or IL2 ELIspot assays. TH1/TH2 ratios will be measured by analysing cytokines in the culture supernatants by Luminex® bead protein assay or ELISA. All data collection will be completed by the end of 2010.

—

Secondary

Measure	Time frame
Blood samples will be separated in PBMC's and plasma samples. The plasma samples will be used to measure antibody responses against the various proteins of B. pertussis as well as against the other proteins of the DKT-IPV-HIB vaccine. Plasma parameter assays: 1. Pertussis (PT, PRN, FHA, FIM2 and FIM3): IgG antibody titer is measured in an ELISA/Luminex® with two-fold serial dilution series in duplicate using FDA reference serum as standard (EU/ml) 2. Diphtheria, tetanus: IgG antibody titer is measured in a ToBI-ELSA/Luminex® with twofold serial dilution series in duplicate using the national reference serum (IU/ml) as standard which is calibrated on the World Health Organization (WHO) standard 3. Haemophilus influenzae type b (Hib): IgG antibody titer is measured in an ELISA/Luminex® with two-fold serial dilution series in duplicate using CBER-FDA reference serum as standard (µg/ml) 4. Polio: total Ig is measured in a neutralisation assay on Vero cells with two-fold serial dilution series in duplicate using the WHO reference serum as standard 5. To monitor the effect of WCV or ACV on TH2 mediated disease manifestations, total IgE levels and some components of the DTP-IPV-Hib vaccine (PT and tetanus) will be measured in the plasma 6. Mucosal IgA antibodies will be measured in the plasmas All data collection will be completed by the end of 2010.	—

Measure

Time frame

Blood samples will be separated in PBMC's and plasma samples. The plasma samples will be used to measure antibody responses against the various proteins of B. pertussis as well as against the other proteins of the DKT-IPV-HIB vaccine. Plasma parameter assays: 1. Pertussis (PT, PRN, FHA, FIM2 and FIM3): IgG antibody titer is measured in an ELISA/Luminex® with two-fold serial dilution series in duplicate using FDA reference serum as standard (EU/ml) 2. Diphtheria, tetanus: IgG antibody titer is measured in a ToBI-ELSA/Luminex® with twofold serial dilution series in duplicate using the national reference serum (IU/ml) as standard which is calibrated on the World Health Organization (WHO) standard 3. Haemophilus influenzae type b (Hib): IgG antibody titer is measured in an ELISA/Luminex® with two-fold serial dilution series in duplicate using CBER-FDA reference serum as standard (µg/ml) 4. Polio: total Ig is measured in a neutralisation assay on Vero cells with two-fold serial dilution series in duplicate using the WHO reference serum as standard 5. To monitor the effect of WCV or ACV on TH2 mediated disease manifestations, total IgE levels and some components of the DTP-IPV-Hib vaccine (PT and tetanus) will be measured in the plasma 6. Mucosal IgA antibodies will be measured in the plasmas All data collection will be completed by the end of 2010.

—

Countries

Netherlands

Outcome results

None listed